Future Retail shares tank 5% on Q1 loss of Rs 562 crore

In Q1FY21, the company incurred a net loss of Rs 561.95 crore against a profit of Rs 159.24 crore in the corresponding quarter a year ago.

Shares of Future Retail tanked 5 percent in the first half of the trading session on BSE on September 15, a day after the company reported its June quarter scorecard.

In Q1FY21, the company incurred a net loss of Rs 561.95 crore against a profit of Rs 159.24 crore in the corresponding quarter a year ago.

Revenue from operations for the June quarter stood at Rs 1,358.11 crore against Rs 5,197.11 crore year-on-year (YoY).

The company said the COVID-19 pandemic and consequent lockdown imposed throughout the country had a significant adverse impact on the business operations and the financial results of the company for the quarter ended June 30, 2020.

Reliance Industries (RIL) on August 29 said it was acquiring the retail and wholesale business and the logistics and warehousing business of rival Future Group for a cash consideration of Rs 24,713 crore in a deal which is likely to give the oil and telecom conglomerate a stronghold in grocery and apparel segments.

The deal is being seen as the coming together of a future digital giant and a retail goliath popularly known to be the veteran of the consumer story in India.

The retail market is still primarily served by the conventional brick-and-mortar stores which account for over 88 percent of the total market. The organised retail is pegged at $60 billion which is expected to witness a rise of 22-25 percent with market size of $140-160 billion by 2021, according to recent industry reports.

Comments

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...

Similar to 2020, D-Street is at record high ahead of Budget 2021; will history repeat itself?

Experts are of the view that a repeat of 2020 or what happened in March might not be possible but some consolidation cannot be ruled out. Back in March when everyone wanted to write-off 2020 from their books, hope and liquidity supported markets and investor sentiment. Nobody thought that after touching a 3-year low in March 2020, benchmark indices would give double-digit returns by the end of the year. The S&P BSE Sensex and Nifty50 rallied by about 15 percent in 2020 and the big outperformance came from the small and midcap stocks. The rally is still continuing in 2021. The S&P BSE Sensex, which climbed Mount 49K, is up over 3 percent while the Nifty50 is up over 4 percent so far in January. Sensex scaling the 49,000-mark and Nifty50 touching 14,500 levels ahead of the Budget 2021 could make anyone cautious about the strength of the rally. Back in January 2020, both Sensex and Nifty touched fresh highs ahead of Budget, and then the market fell like a pack of cards. The ...

SD Solutions

Search This Blog